Team

Group Founder

Stanley Chang

• MD in Medicine (National Taiwan University College of Medicine)
• Ph.D. in Biophysics (UCL, University of London, UK)

Stanley has more than 40 years of experience in the biomedical industry. He began his career at National Taiwan University Hospital as a resident and a chief resident in the department of urology. He also served as the chairman of department of urology at Tzu-Chi General Hospital. He established Medigen Biotechnology Corp. (MBC) focusing on the development of new therapies for liver diseases and cancers. in late 1999. MBC has now gradually developed into a comprehensive biopharmaceutical corporation with business fields covering new drug development, innovative drug discovery, molecular diagnostics, vaccine, and generic drugs.

Chief Executive Officer

Willy Hsu

• Ph.D. in immunology (University of California)
• Bachelor of Science (University of California)

15-year experience in oversea sales of HLA kits and over ten years of corporate management at VP levels. He was the Chief Scientist of ASHI Lab in TBG Taiwan, Sales Manager (USA), and Oversea Sales Director of TBG.

Chief Financial Officer

Fanny Hu

• B.B.A. in Accounting (Soochow University)

Fanny began her career at Medigen Biotechnology Corp. (MBC) after graduating from university. She is in charge of accounting operations and responsible for multiple tasks including fundraising, capital needs, and investment management. She is an executive director and was appointed as the chief financial officer of U-Gen on January 1, 2019.

Head of Early Assessment

Dino Kuan

• Bachelor’s Degree in Pharmacy, Taipei Medical University
• Executive Master of Business Administration (EMBA), Chaoyang University of Technology
• Licensed Pharmacist
• Executive Assistant to the Chairman, Medigen Biotechnology Corp.
• With extensive leadership experience, including roles as Business Group Manager and Director of Sales in Pfizer, Novartis, Mundipharma and Lotus International Pharmaceutical

Head of General Screening

Peter Lai

• President of WinMEMS Technologies
• Ph.D. in Electrical Engineering (University of Southern California)

Dr. Lai first joined Vincera Ventures in 1998 after graduating from the University of Southern California. He was responsible for investing in many companies in the USA and Taiwan, and also as a Board member. In 2008, he founded WinMEMS Technologies to start his entrepreneurship. In the past years, he led WinMEMS to develop the multiplex diagnostic platform, so-called the EMMB (EdgeCode Multiplex Magnetic Bead) system. He is also the principal inventor of the EdgeCode patent.  WinMEMS was acquired by U-Gen in 2021 and Dr. Lai keeps leading this company as the CEO and is in charge of the business of U-Gen for general screening projects.

Head of Early Diagnosis

Jin-Lei Liu

• Master of medical genetics, Central South University,  China
• With over 15 years of experience in IVD kit sales and LDT services in the Chinese market, Mr. Liu has held key positions such as Regional Manager at Merck, Strategy Director at Genetalks, and General Manager at AMPRING. In 2016, he founded Hunan Yearth Co., Ltd., where he led the team in developing multiple diagnostic kits based on the NGS platform, securing several patents. Following Yearth’s acquisition by U-Gen in 2021, Mr. Liu continued to serve as CEO and is responsible for U-Gen’s Early Diagnosis projects.